BIOMAT Database Logo BIOMAT Database Logo

Sulfonylbenzoyl-nitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase. 1991

P M Traxler, and O Wacker, and H L Bach, and J F Geissler, and W Kump, and T Meyer, and U Regenass, and J L Roesel, and N Lydon
Oncology and Virology Research Department, Ciba-Geigy Ltd., Basel, Switzerland.

The synthesis and biological activities of a series of sulfonylbenzoyl-nitrostyrene derivatives, a novel class of selective bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase, are described. The most potent derivatives inhibited the EGF-R tyrosine kinase, using angiotensin II as exogenous substrate, with IC50 values of less than or equal to 1 microM. No inhibition of the v-abl tyrosine kinase or the serine/threonine kinases PKC and PK-A was observed. In addition, active derivatives (compounds 5 and 12) effectively blocked the autophosphorylation of the EGF-R in vitro. Starting from the acids 5, 7, and 9, a series of esters, amides, and peptides was synthesized with the aim of increasing cellular penetration. Amides 14-18 showed potent antiproliferative effects using the EGF-dependent Balb/MK mouse epidermal keratinocyte cell line. Additionally, with the amide 14 inhibition of EGF-R autophosphorylation was demonstrated in the A431 cell line. CAMM studies using a computer-generated model for the transition state of the gamma-phosphoryl transfer from ATP to a tyrosine moiety and fitting experiments using the highly potent derivative 7 (IC50 value = 54 nM) support the hypothesis that the sulfonylbenzoyl group mimics a diphosphate moiety in the transition state. These results demonstrate that the rational design of tyrosine kinase inhibitors, using the inhibitory nitrostyrene moiety as a tyrosine mimic together with the sulfonylbenzoyl moiety as a diphosphate mimic, leads to highly potent and selective multisubstrate type inhibitors.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009574 Nitro Compounds Compounds having the nitro group, -NO2, attached to carbon. When attached to nitrogen they are nitramines and attached to oxygen they are NITRATES. Nitrated Compounds
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002621 Chemistry A basic science concerned with the composition, structure, and properties of matter; and the reactions that occur between substances and the associated energy exchange.
D003198 Computer Simulation Computer-based representation of physical systems and phenomena such as chemical processes. Computational Modeling,Computational Modelling,Computer Models,In silico Modeling,In silico Models,In silico Simulation,Models, Computer,Computerized Models,Computer Model,Computer Simulations,Computerized Model,In silico Model,Model, Computer,Model, Computerized,Model, In silico,Modeling, Computational,Modeling, In silico,Modelling, Computational,Simulation, Computer,Simulation, In silico,Simulations, Computer
D003461 Crystallography The branch of science that deals with the geometric description of crystals and their internal arrangement. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Crystallographies
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations

Related Publications

P M Traxler, and O Wacker, and H L Bach, and J F Geissler, and W Kump, and T Meyer, and U Regenass, and J L Roesel, and N Lydon
Tyrosine kinase inhibitors against EGF receptor-positive malignancies.
January 2001, Methods in molecular biology (Clifton, N.J.),
P M Traxler, and O Wacker, and H L Bach, and J F Geissler, and W Kump, and T Meyer, and U Regenass, and J L Roesel, and N Lydon
Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase.
April 1994, Journal of medicinal chemistry,
P M Traxler, and O Wacker, and H L Bach, and J F Geissler, and W Kump, and T Meyer, and U Regenass, and J L Roesel, and N Lydon
Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors.
February 2012, Cellular signalling,
P M Traxler, and O Wacker, and H L Bach, and J F Geissler, and W Kump, and T Meyer, and U Regenass, and J L Roesel, and N Lydon
Growth inhibition of nasopharyngeal carcinoma cells by EGF receptor tyrosine kinase inhibitors.
January 1999, Anticancer research,
P M Traxler, and O Wacker, and H L Bach, and J F Geissler, and W Kump, and T Meyer, and U Regenass, and J L Roesel, and N Lydon
4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase.
June 1996, Journal of medicinal chemistry,
P M Traxler, and O Wacker, and H L Bach, and J F Geissler, and W Kump, and T Meyer, and U Regenass, and J L Roesel, and N Lydon
Cell-penetrating bisubstrate-based protein kinase C inhibitors.
July 2013, ACS chemical biology,
P M Traxler, and O Wacker, and H L Bach, and J F Geissler, and W Kump, and T Meyer, and U Regenass, and J L Roesel, and N Lydon
Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells.
June 2007, Proceedings of the National Academy of Sciences of the United States of America,
P M Traxler, and O Wacker, and H L Bach, and J F Geissler, and W Kump, and T Meyer, and U Regenass, and J L Roesel, and N Lydon
Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors.
April 2011, International journal of clinical and experimental pathology,
P M Traxler, and O Wacker, and H L Bach, and J F Geissler, and W Kump, and T Meyer, and U Regenass, and J L Roesel, and N Lydon
Design of potent protein kinase inhibitors using the bisubstrate approach.
January 1991, Journal of medicinal chemistry,
P M Traxler, and O Wacker, and H L Bach, and J F Geissler, and W Kump, and T Meyer, and U Regenass, and J L Roesel, and N Lydon
Receptor tyrosine kinase inhibitors.
February 2001, Current opinion in investigational drugs (London, England : 2000),
Copied contents to your clipboard!